vs

Side-by-side financial comparison of FIRSTSUN CAPITAL BANCORP (FSUN) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $110.0M, roughly 1.4× FIRSTSUN CAPITAL BANCORP). FIRSTSUN CAPITAL BANCORP runs the higher net margin — 19.6% vs -5.5%, a 25.1% gap on every dollar of revenue. Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 6.9%).

FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

FSUN vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.4× larger
TARS
$151.7M
$110.0M
FSUN
Higher net margin
FSUN
FSUN
25.1% more per $
FSUN
19.6%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
6.9%
FSUN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FSUN
FSUN
TARS
TARS
Revenue
$110.0M
$151.7M
Net Profit
$21.6M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
19.6%
-5.5%
Revenue YoY
128.4%
Net Profit YoY
-8.4%
63.8%
EPS (diluted)
$0.76
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSUN
FSUN
TARS
TARS
Q1 26
$110.0M
Q4 25
$110.2M
$151.7M
Q3 25
$107.3M
$118.7M
Q2 25
$105.6M
$102.7M
Q1 25
$96.2M
$78.3M
Q4 24
$98.7M
$66.4M
Q3 24
$98.2M
$48.1M
Q2 24
$96.2M
$40.8M
Net Profit
FSUN
FSUN
TARS
TARS
Q1 26
$21.6M
Q4 25
$24.8M
$-8.4M
Q3 25
$23.2M
$-12.6M
Q2 25
$26.4M
$-20.3M
Q1 25
$23.6M
$-25.1M
Q4 24
$16.4M
$-23.1M
Q3 24
$22.4M
$-23.4M
Q2 24
$24.6M
$-33.3M
Operating Margin
FSUN
FSUN
TARS
TARS
Q1 26
Q4 25
29.0%
-5.3%
Q3 25
26.4%
-12.2%
Q2 25
31.2%
-21.6%
Q1 25
30.9%
-33.5%
Q4 24
20.4%
-36.8%
Q3 24
29.1%
-52.3%
Q2 24
32.3%
-81.6%
Net Margin
FSUN
FSUN
TARS
TARS
Q1 26
19.6%
Q4 25
22.5%
-5.5%
Q3 25
21.6%
-10.6%
Q2 25
25.0%
-19.8%
Q1 25
24.5%
-32.1%
Q4 24
16.6%
-34.8%
Q3 24
22.8%
-48.7%
Q2 24
25.5%
-81.6%
EPS (diluted)
FSUN
FSUN
TARS
TARS
Q1 26
$0.76
Q4 25
$0.89
$-0.17
Q3 25
$0.82
$-0.30
Q2 25
$0.93
$-0.48
Q1 25
$0.83
$-0.64
Q4 24
$0.57
$-0.57
Q3 24
$0.79
$-0.61
Q2 24
$0.88
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSUN
FSUN
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$413.7M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.2B
$343.4M
Total Assets
$8.6B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSUN
FSUN
TARS
TARS
Q1 26
$413.7M
Q4 25
$652.6M
$417.3M
Q3 25
$659.9M
$401.8M
Q2 25
$785.1M
$381.1M
Q1 25
$621.4M
$407.9M
Q4 24
$615.9M
$291.4M
Q3 24
$573.7M
$317.0M
Q2 24
$535.8M
$323.6M
Total Debt
FSUN
FSUN
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
FSUN
FSUN
TARS
TARS
Q1 26
$1.2B
Q4 25
$1.2B
$343.4M
Q3 25
$1.1B
$335.1M
Q2 25
$1.1B
$332.6M
Q1 25
$1.1B
$342.5M
Q4 24
$1.0B
$224.5M
Q3 24
$1.0B
$237.5M
Q2 24
$996.6M
$252.2M
Total Assets
FSUN
FSUN
TARS
TARS
Q1 26
$8.6B
Q4 25
$8.5B
$562.2M
Q3 25
$8.5B
$534.6M
Q2 25
$8.4B
$495.0M
Q1 25
$8.2B
$500.8M
Q4 24
$8.1B
$377.0M
Q3 24
$8.1B
$376.3M
Q2 24
$8.0B
$376.8M
Debt / Equity
FSUN
FSUN
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSUN
FSUN
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSUN
FSUN
TARS
TARS
Q1 26
Q4 25
$111.5M
$19.3M
Q3 25
$49.4M
$18.3M
Q2 25
$15.0M
$-29.4M
Q1 25
$26.4M
$-20.7M
Q4 24
$101.1M
$-22.2M
Q3 24
$48.1M
$-8.7M
Q2 24
$20.9M
$-14.4M
Free Cash Flow
FSUN
FSUN
TARS
TARS
Q1 26
Q4 25
$104.0M
$13.0M
Q3 25
$47.6M
$16.3M
Q2 25
$13.0M
$-30.4M
Q1 25
$24.3M
$-21.2M
Q4 24
$95.7M
$-22.3M
Q3 24
$47.1M
$-8.9M
Q2 24
$19.9M
$-15.4M
FCF Margin
FSUN
FSUN
TARS
TARS
Q1 26
Q4 25
94.3%
8.6%
Q3 25
44.4%
13.8%
Q2 25
12.3%
-29.6%
Q1 25
25.3%
-27.1%
Q4 24
97.0%
-33.5%
Q3 24
47.9%
-18.6%
Q2 24
20.6%
-37.8%
Capex Intensity
FSUN
FSUN
TARS
TARS
Q1 26
Q4 25
6.8%
4.2%
Q3 25
1.6%
1.6%
Q2 25
1.9%
1.0%
Q1 25
2.1%
0.8%
Q4 24
5.5%
0.1%
Q3 24
1.1%
0.6%
Q2 24
1.1%
2.5%
Cash Conversion
FSUN
FSUN
TARS
TARS
Q1 26
Q4 25
4.49×
Q3 25
2.13×
Q2 25
0.57×
Q1 25
1.12×
Q4 24
6.18×
Q3 24
2.15×
Q2 24
0.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FSUN
FSUN

Net Interest Income$82.8M75%
Noninterest Income$27.2M25%

TARS
TARS

Segment breakdown not available.

Related Comparisons